SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Microscopes, books and test tubes amidst colorful balls on a pink background.-3d rendering."n
FDA
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of new approach methodologies, experts told BioSpace, particularly emphasizing the agency’s recommendations around defining NAMs’ regulatory purpose.
March 24, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Symbolic image: Tablets, US Dollar and China - Dependence on the Chinese pharmaceutical industry
Manufacturing
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
March 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Obesity
Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns
Aardvark Therapeutics’ obesity asset is based on its lead molecule, which in February was linked to reversible heart safety signals in a healthy volunteer study.
March 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Gilead Sciences CEO Daniel O’Day (Gilead)
People
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club
Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.
March 24, 2026
 · 
2 min read
 · 
Tristan Manalac
A train with blue background, 3d rendering. Computer digital drawing.
Mergers & acquisitions
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos
Following last month’s $7.8 billion purchase of CAR T biotech Arcellx, Gilead’s dealmaking train chugs along with yet another acquisition—this time securing Ouro Medicines’ pipeline of T cell engagers for inflammatory diseases.
March 24, 2026
 · 
3 min read
 · 
Tristan Manalac
illustration of the ship in the storm, gigantic waves
Opinion
Biotechs Must Face Reality To Succeed in Today’s Funding Environment
The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people think.
March 24, 2026
 · 
5 min read
 · 
Ali Pashazadeh
3d illustration of a national flag with a grunge metal texture
Opinion
Japan’s Drug Prices Are Creating Problems for Washington and Tokyo Alike
If the U.S. can help Japan reform its drug pricing controls, both countries stand to benefit.
March 24, 2026
 · 
4 min read
 · 
John Stanford
Illustration of a business person giving a presentation in front of a board of directors, vector illustration
Business
Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite
Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the company at the heart of former CDER Director George Tidmarsh’s exit from the FDA.
March 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Checklist collage banner with halftone hands. Hand holding marker and putting a check mark or cross in checkbox. Collage design with halftone elements. Concept of check list. Vector illustration.
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.
March 23, 2026
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS